Zura Bio Q4 2024 Earnings Report

Zura Bio EPS Results

• Actual EPS: -$0.08
• Consensus EPS: -$0.17
• Beat/Miss: Beat by +$0.09
• One Year Ago EPS: N/A

Zura Bio Revenue Results

• Actual Revenue: $0.00 million
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Zura Bio Announcement Details

• Quarter: Q4 2024
• Date: 3/25/2025
• Time: Before Market Opens
• Conference Call Date: Tuesday, March 25, 2025
• Conference Call Time: 7:00AM ET

Zura Bio (NASDAQ:ZURA), Inc. is a clinical-stage biotechnology company focused on the development of next-generation protein bioconjugates for therapeutic and diagnostic applications. Leveraging a proprietary platform for site-specific incorporation of non-canonical amino acids, the company aims to create highly targeted conjugates that improve drug delivery, enhance imaging contrast, and reduce off-target toxicity. Zura Bio’s technology is designed to streamline the manufacturing process by enabling precise attachment of payloads—such as cytotoxic drugs or imaging agents—to protein scaffolds without affecting their native structure or function.

The company’s research and development activities center on expanding its platform across multiple therapeutic areas, including oncology, immunology and rare diseases. By combining advanced protein engineering with established conjugation chemistry, Zura Bio seeks to generate a pipeline of drug candidates that offer superior stability, optimized pharmacokinetics and enhanced safety profiles. Preclinical studies to date have demonstrated the potential of these conjugates to achieve targeted delivery while minimizing systemic exposure.

In addition to its internal pipeline, Zura Bio collaborates with academic institutions and industry partners to explore novel applications of its bioconjugation technology. These partnerships are intended to accelerate the translation of platform innovations into clinical-stage programs and to broaden the range of payloads that can be delivered using site-specific conjugation methods. The company’s approach is designed to be modular, allowing collaborators to integrate payloads of interest onto clinically proven protein backbones.

Based in Berkeley, California, Zura Bio serves global markets by engaging with biotechnology and pharmaceutical companies seeking to enhance the performance of their protein-based therapeutics and diagnostic tools. With a leadership team experienced in protein engineering and drug development, the company is positioned to advance its conjugation platform toward first-in-human studies and to establish strategic alliances that further validate the broad utility of its technology.